Fundraising FoxNorthpond Ventures — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.
AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB
Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in
Co-investorsGV (Google Ventures)SV Health InvestorsForbionJohnson & Johnson Innovation – JJDCJJDC
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in
Co-investorsARCH Venture PartnersM VenturesIllumina VenturesNovalis LifeSciences
Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.
Media & Entertainment
Co-investorsAgate Medical Investments LPSCP Vitalife PartnersForbionGV (Google Ventures)SV Health Investors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.